Plain-English translation of NCT07258290 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing a new heart device called the Freesolve Sirolimus Eluting Coronary Resorbable Magnesium Scaffold — a small tube designed to open blocked arteries in your heart. Unlike traditional stents that stay in your artery permanently, this new scaffold gradually dissolves over time. Researchers want to see if this treatment works just as well as, or better than, the current standard metal stent.
Many people who get stents placed in their heart arteries face long-term complications because the metal stent stays there forever. This medication is designed to dissolve on its own after it has done its job, which researchers hope could reduce these long-term problems and improve outcomes for heart patients.
You likely qualify if…
You likely don't qualify if…
If you join this study, you will undergo a heart catheterization procedure where doctors will place either the new dissolvable scaffold or a traditional stent in your coronary artery. You will then be followed up at 1, 6, and 12 months after the procedure, and then again at 2, 3, 4, and 5 years to monitor how well the treatment is working and check for any side effects. About two-thirds of participants will receive the new scaffold, while one-third will receive the traditional stent for comparison.
AI-generated summary from trial data · Jul 10, 2026 · Not medical advice
United States